Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.53 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗
Via The Motley Fool
News headline image
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on CRSP Options ↗
 
Via Benzinga
News headline image
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
1 big new Green Flag for CRISPR Therapeutics' Stock ↗
Via The Motley Fool
News headline image
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
The Ultimate Healthcare Stock to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗
Via The Motley Fool
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
News headline image
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox ↗
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
My Top 5 Stocks to Buy in Early 2025 ↗
Via The Motley Fool
News headline image
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia ↗
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares. 
Via Benzinga
Topics Artificial Intelligence
News headline image
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗
Via The Motley Fool
News headline image
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
News headline image
My 10 Top Stocks to Buy to Start the New Year Off Right ↗
Via The Motley Fool
News headline image
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗
Via The Motley Fool
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
3 Mid-Cap Stocks That Could Take Off in 2025 ↗
Via The Motley Fool
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.